McKesson Corporation (MCK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, McKesson Corporation (MCK) has a cash flow conversion efficiency ratio of -12.444x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.23 Billion) by net assets ($-99.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
McKesson Corporation - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how McKesson Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read McKesson Corporation total liabilities for a breakdown of total debt and financial obligations.
McKesson Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of McKesson Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Duke Energy Corporation
NYSE:DUK
|
0.069x |
|
Rio Tinto Group
F:RIOA
|
0.046x |
|
Brookfield Corporation
TO:BN
|
0.018x |
|
Hon Hai Precision Industry Co Ltd
TW:2317
|
-0.039x |
|
Equinor ASA
OL:EQNR
|
0.494x |
|
BNP PARIBAS ADR 1/2/EO 2
F:BNPH
|
N/A |
|
Enel SpA
F:ENLA
|
0.085x |
|
Southern Company
NYSE:SO
|
0.099x |
Annual Cash Flow Conversion Efficiency for McKesson Corporation (1995–2025)
The table below shows the annual cash flow conversion efficiency of McKesson Corporation from 1995 to 2025. For the full company profile with market capitalisation and key ratios, see MCK market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $-1.69 Billion | $6.08 Billion | -3.592x | -33.14% |
| 2024-03-31 | $-1.60 Billion | $4.31 Billion | -2.698x | +22.08% |
| 2023-03-31 | $-1.49 Billion | $5.16 Billion | -3.462x | -39.93% |
| 2022-03-31 | $-1.79 Billion | $4.43 Billion | -2.474x | -178.77% |
| 2021-03-31 | $1.45 Billion | $4.54 Billion | 3.141x | +381.93% |
| 2020-03-31 | $6.71 Billion | $4.37 Billion | 0.652x | +56.32% |
| 2019-03-31 | $9.68 Billion | $4.04 Billion | 0.417x | +10.51% |
| 2018-03-31 | $11.52 Billion | $4.34 Billion | 0.377x | +0.21% |
| 2017-03-31 | $12.60 Billion | $4.74 Billion | 0.377x | +6.78% |
| 2016-03-31 | $10.41 Billion | $3.67 Billion | 0.353x | +7.31% |
| 2015-03-31 | $9.47 Billion | $3.11 Billion | 0.329x | +8.11% |
| 2014-03-31 | $10.32 Billion | $3.14 Billion | 0.304x | -13.46% |
| 2013-03-31 | $7.07 Billion | $2.48 Billion | 0.351x | -18.68% |
| 2012-03-31 | $6.83 Billion | $2.95 Billion | 0.432x | +33.36% |
| 2011-03-31 | $7.22 Billion | $2.34 Billion | 0.324x | +5.31% |
| 2010-03-31 | $7.53 Billion | $2.32 Billion | 0.307x | +40.95% |
| 2009-03-31 | $6.19 Billion | $1.35 Billion | 0.218x | +53.66% |
| 2008-03-31 | $6.12 Billion | $869.00 Million | 0.142x | -42.13% |
| 2007-03-31 | $6.27 Billion | $1.54 Billion | 0.245x | -47.19% |
| 2006-03-31 | $5.91 Billion | $2.74 Billion | 0.465x | +59.29% |
| 2005-03-31 | $5.28 Billion | $1.54 Billion | 0.292x | +167.37% |
| 2004-03-31 | $5.17 Billion | $563.40 Million | 0.109x | -25.90% |
| 2003-03-31 | $4.72 Billion | $695.50 Million | 0.147x | +84.89% |
| 2002-03-31 | $4.14 Billion | $329.30 Million | 0.080x | -16.83% |
| 2001-03-31 | $3.69 Billion | $353.10 Million | 0.096x | +186.55% |
| 2000-03-31 | $3.76 Billion | $-416.00 Million | -0.111x | -207.33% |
| 1999-03-31 | $3.08 Billion | $317.10 Million | 0.103x | +7404.23% |
| 1998-03-31 | $1.60 Billion | $2.20 Million | 0.001x | -99.16% |
| 1997-03-31 | $1.46 Billion | $238.10 Million | 0.164x | +7239.94% |
| 1996-03-31 | $1.12 Billion | $2.50 Million | 0.002x | -98.77% |
| 1995-03-31 | $1.07 Billion | $195.10 Million | 0.182x | -- |
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related produc… Read more